US FDA says no, again, to Vanda’s tradipitant in gastroparesis
The U.S. path forward is narrowing for Vanda Pharmaceuticals Inc.’s tradipitant as a treatment for gastroparesis, a serious disorder for which there’s been no new treatment in several decades.
MS
mari serebrov
via Bioworld
Updated 3h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Fed is watching energy price spikes, but Chair Powell says bank is limited in what it can do
Next
Tinubu seeks Senate's approval for fresh $6bn loans from UAE, UK
Related Articles
ScienceSlack adds 30 AI features to Slackbot, its most ambitious update since the Salesforce acquisition
Venturebeat-13h ago-1 sources
ScienceOBIO® Celebrates Women Leaders in Life Sciences and Health Tech with Investment in Block Biosciences and Launch of Entrepreneurship Training Program for Women in STEM
Businesswire-13h ago-1 sources
ScienceHow a statistical paradox can make research findings fall apart
Scientificamerican-13h ago-1 sources